Table 3 |
|||||||||
|
IHC profile of the studied cases |
|||||||||
|
Provisional diagnosis |
Vimentin |
CK |
S100 |
Desmin |
SMA |
CD34 |
CD10 |
Final diagnosis |
|
|
|
|||||||||
|
1 |
SCL? |
+ |
- |
- |
- |
- |
+ |
- |
SCL |
|
2 |
MFB? |
+ |
- |
- |
+ |
+/- |
+ |
- |
MFB |
|
3 |
Benign BSCTs? |
+ |
- |
- |
- |
+ |
- |
Fibromatosis |
|
|
4 |
Benign BSCTs? |
- |
+ |
+ |
- |
+/- |
- |
-/+ |
ME |
|
5 |
Malignant PT? |
- |
+ |
+ |
- |
-/+ |
+/- |
MME |
|
|
6 |
leiomyoma |
+ |
- |
- |
+ |
+ |
- |
- |
Leiomyoma |
|
7 |
leiomyosarcoma |
+ |
- |
- |
+ |
+ |
- |
- |
Leiomyosarcoma |
|
8 |
Malignant BSCTs? |
-/+ |
+ |
+ |
- |
+ |
- |
+ |
SCC |
|
|
|||||||||
|
- negative. -/+ rare cells not exceeding 10% of the total population. +/-between 10 and 50%. + more than 50%. |
|||||||||
|
Abd El All Diagnostic Pathology 2006 1:13 doi:10.1186/1746-1596-1-13 |
|||||||||
